<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:department>Barts Cancer Institute</gtr:department><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/8B535EAD-DA0A-4964-85F4-04B4144ACEE9"><gtr:id>8B535EAD-DA0A-4964-85F4-04B4144ACEE9</gtr:id><gtr:firstName>Kairbaan</gtr:firstName><gtr:surname>Hodivala-Dilke</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/64DFF7A7-D215-40F1-B063-5AA56F016370"><gtr:id>64DFF7A7-D215-40F1-B063-5AA56F016370</gtr:id><gtr:firstName>Louise</gtr:firstName><gtr:surname>Reynolds</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0901609"><gtr:id>69B97835-7F31-4E45-8EA9-1FFDA80B4015</gtr:id><gtr:title>Elucidating the role of JAM-B in breast cancer and angiogenesis</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0901609</gtr:grantReference><gtr:abstractText>Breast cancer is the most common cancer in women in the UK, but how angiogenesis is regulated in breast cancer is unknown. The growth of blood vessels into tumours (angiogenesis) is essential for cancer growth, and anti-angiogenic therapy is an important new strategy to treat cancer. Interestingly, women with Down Syndrome very rarely develop breast cancer, possibly as a result of the presence of three copies of chromosome 21. We will determine how three copies of chromosome 21 suppresses breast cancer angiogenesis. I will focus upon the involvement of a specific chromosome 21 molecule, termed JAM-B, which we already have evidence for a role in angiogenesis. I will use both clinical material and experimental mouse models. This research will help us to understand the disease better and possibly lead to the development of therapies to inhibit breast cancer progression.</gtr:abstractText><gtr:technicalSummary>Down Syndrome (DS) is a genetic disorder caused by full or partial trisomy of chromosome 21. It presents with many clinical phenotypes including a reduced incidence of solid tumours, in particular breast cancer. This phenotype is thought to occur as a consequence of chromosome 21 ?gene-dosage? effects and suppression of angiogenesis. We will use the transchromosomic (Tc1) mouse model of DS, which expresses 81% of human chromosome 21 (Hsa21) genes, to understand why individuals with DS have a reduced incidence of breast cancer. We will focus on the gene-dosage effect of the JAM-B gene, located on Hsa21. We have compelling preliminary showing that JAM-B, an endothelial cell-specific gene, when overexpressed, is responsible for the inhibition of tumour angiogenesis. We will breed Tc1 mice with JAM-B transgenic mice to generate mice that have 2 copies of JAM-B (Tc1/JAM-B+/-). Using both Tc1 and Tc1/JAM-B+/- mice we will i) examine the gene-dosage effect of JAM-B on breast cancer and angiogenesis and ii) understand the mechanism of action of JAM-B in the regulation of angiogenesis.By using an interdisciplinary approach combining angiogenesis assays with the Tc1 DS model we will identify the gene-dosage effect of JAM-B on breast cancer and tumour angiogenesis.</gtr:technicalSummary><gtr:fund><gtr:end>2014-01-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-02-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>374592</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/84B826D2-6B0E-4351-9945-14832C46D136"><gtr:id>84B826D2-6B0E-4351-9945-14832C46D136</gtr:id><gtr:title>FAK-heterozygous mice display enhanced tumour angiogenesis.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ef4149ccc533c98d0def3e3513beaafe"><gtr:id>ef4149ccc533c98d0def3e3513beaafe</gtr:id><gtr:otherNames>Kostourou V.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/21C92A4E-9BB5-48AF-8C51-F91C75EE6398"><gtr:id>21C92A4E-9BB5-48AF-8C51-F91C75EE6398</gtr:id><gtr:title>FAK-heterozygous mice display enhanced tumour angiogenesis.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ef4149ccc533c98d0def3e3513beaafe"><gtr:id>ef4149ccc533c98d0def3e3513beaafe</gtr:id><gtr:otherNames>Kostourou V.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/891BE2DC-B186-474D-B8BF-D4622EF754AC"><gtr:id>891BE2DC-B186-474D-B8BF-D4622EF754AC</gtr:id><gtr:title>Contribution of ADAMTS1 as a tumor suppressor gene in human breast carcinoma. Linking its tumor inhibitory properties to its proteolytic activity on nidogen-1 and nidogen-2.</gtr:title><gtr:parentPublicationTitle>International journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4a38e7323b89f9676c2024095e39bd7a"><gtr:id>4a38e7323b89f9676c2024095e39bd7a</gtr:id><gtr:otherNames>Martino-Echarri E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0020-7136</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/252CB61E-99DC-408A-BC83-BDEB10CF8257"><gtr:id>252CB61E-99DC-408A-BC83-BDEB10CF8257</gtr:id><gtr:title>Pancreatic stellate cells regulate blood vessel density in the stroma of pancreatic ductal adenocarcinoma.</gtr:title><gtr:parentPublicationTitle>Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0a1f1796b39d50b7501b391a7b910b6e"><gtr:id>0a1f1796b39d50b7501b391a7b910b6e</gtr:id><gtr:otherNames>Di Maggio F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1424-3903</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FE6EBEDD-8E1A-4E9F-9E2C-988E838C5FC8"><gtr:id>FE6EBEDD-8E1A-4E9F-9E2C-988E838C5FC8</gtr:id><gtr:title>Endothelial FAK is required for tumour angiogenesis.</gtr:title><gtr:parentPublicationTitle>EMBO molecular medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/678080c2bc9979d4354d26836d0a6212"><gtr:id>678080c2bc9979d4354d26836d0a6212</gtr:id><gtr:otherNames>Tavora B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1757-4676</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EDE43E16-237C-46D6-B79C-4D963B87ECE4"><gtr:id>EDE43E16-237C-46D6-B79C-4D963B87ECE4</gtr:id><gtr:title>Endothelial-cell FAK targeting sensitizes tumours to DNA-damaging therapy.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/678080c2bc9979d4354d26836d0a6212"><gtr:id>678080c2bc9979d4354d26836d0a6212</gtr:id><gtr:otherNames>Tavora B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/345D003A-5B73-434A-A85E-53E28237918B"><gtr:id>345D003A-5B73-434A-A85E-53E28237918B</gtr:id><gtr:title>Tumour angiogenesis is reduced in the Tc1 mouse model of Down's syndrome.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/660305fa92a9e0d3cf4b20bff1475fb2"><gtr:id>660305fa92a9e0d3cf4b20bff1475fb2</gtr:id><gtr:otherNames>Reynolds LE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F6B13008-F34E-416F-AB73-3232ABCFC32F"><gtr:id>F6B13008-F34E-416F-AB73-3232ABCFC32F</gtr:id><gtr:title>Tumour-associated endothelial-FAK correlated with molecular sub-type and prognostic factors in invasive breast cancer.</gtr:title><gtr:parentPublicationTitle>BMC cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e5f64862b3931b8d6c0d0ed5f153beee"><gtr:id>e5f64862b3931b8d6c0d0ed5f153beee</gtr:id><gtr:otherNames>Alexopoulou AN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1471-2407</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FFE78549-5FDE-4D1F-85D8-D65AFC64BB27"><gtr:id>FFE78549-5FDE-4D1F-85D8-D65AFC64BB27</gtr:id><gtr:title>A Promyelocytic Leukemia Protein-Thrombospondin-2 Axis and the Risk of Relapse in Neuroblastoma.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b86a27e5113ffbf126c6f3c2d330e868"><gtr:id>b86a27e5113ffbf126c6f3c2d330e868</gtr:id><gtr:otherNames>Dvorkina M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/28668B21-EE0F-4647-A33E-DE3E110EA1B2"><gtr:id>28668B21-EE0F-4647-A33E-DE3E110EA1B2</gtr:id><gtr:title>Suppression of TGF? and Angiogenesis by Type VII Collagen in Cutaneous SCC.</gtr:title><gtr:parentPublicationTitle>Journal of the National Cancer Institute</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5baf1744c4fe9fa5a0a94e258f4d9143"><gtr:id>5baf1744c4fe9fa5a0a94e258f4d9143</gtr:id><gtr:otherNames>Martins VL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0027-8874</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/37A40C44-F2FD-4713-AB5F-33F7BBEDB5A6"><gtr:id>37A40C44-F2FD-4713-AB5F-33F7BBEDB5A6</gtr:id><gtr:title>av?3 Integrin and tumour blood vessels-learning from the past to shape the future.</gtr:title><gtr:parentPublicationTitle>Current opinion in cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0224b230947fd12b1843d9aec63689d5"><gtr:id>0224b230947fd12b1843d9aec63689d5</gtr:id><gtr:otherNames>Demircioglu F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0955-0674</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9DDB1094-2913-4626-ABE4-FA8E1D675D45"><gtr:id>9DDB1094-2913-4626-ABE4-FA8E1D675D45</gtr:id><gtr:title>Stromal Claudin14-heterozygosity, but not deletion, increases tumour blood leakage without affecting tumour growth.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/549cbf805ce7d8520d8a40810c6b0188"><gtr:id>549cbf805ce7d8520d8a40810c6b0188</gtr:id><gtr:otherNames>Baker M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1921A99A-1739-4492-B6A9-2408610F8DA5"><gtr:id>1921A99A-1739-4492-B6A9-2408610F8DA5</gtr:id><gtr:title>Haematopoietic focal adhesion kinase deficiency alters haematopoietic homeostasis to drive tumour metastasis.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ce69e5c0a73e7669ff34d5018097326d"><gtr:id>ce69e5c0a73e7669ff34d5018097326d</gtr:id><gtr:otherNames>Batista S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/920E714C-7CAD-427C-BDD5-63529E9EF856"><gtr:id>920E714C-7CAD-427C-BDD5-63529E9EF856</gtr:id><gtr:title>Generation of point-mutant FAK knockin mice.</gtr:title><gtr:parentPublicationTitle>Genesis (New York, N.Y. : 2000)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/678080c2bc9979d4354d26836d0a6212"><gtr:id>678080c2bc9979d4354d26836d0a6212</gtr:id><gtr:otherNames>Tavora B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1526-954X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C6C4603C-112B-48E6-A616-B7375E8F8905"><gtr:id>C6C4603C-112B-48E6-A616-B7375E8F8905</gtr:id><gtr:title>Molecular Pathways: Endothelial Cell FAK-A Target for Cancer Treatment.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1475f7eb9b7cca8b9eab073f666b4ae5"><gtr:id>1475f7eb9b7cca8b9eab073f666b4ae5</gtr:id><gtr:otherNames>Roy-Luzarraga M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/81EA2138-546C-4F56-8437-9ED34D1EEE89"><gtr:id>81EA2138-546C-4F56-8437-9ED34D1EEE89</gtr:id><gtr:title>Acute depletion of endothelial ?3-integrin transiently inhibits tumor growth and angiogenesis in mice.</gtr:title><gtr:parentPublicationTitle>Circulation research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6c0d956ec0ed62e2d1dc9e8cb3db81b9"><gtr:id>6c0d956ec0ed62e2d1dc9e8cb3db81b9</gtr:id><gtr:otherNames>Steri V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0009-7330</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F7142AA6-491F-4045-BA34-47BBA7856C52"><gtr:id>F7142AA6-491F-4045-BA34-47BBA7856C52</gtr:id><gtr:title>Interleukin-6 Stimulates Defective Angiogenesis.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7a0fcd8b34126782499d3a07f134f63e"><gtr:id>7a0fcd8b34126782499d3a07f134f63e</gtr:id><gtr:otherNames>Gopinathan G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B222FA08-D78B-4048-8875-A9A6E9B3F79F"><gtr:id>B222FA08-D78B-4048-8875-A9A6E9B3F79F</gtr:id><gtr:title>Endogenous ribosomal protein L29 (RPL29): a newly identified regulator of angiogenesis in mice.</gtr:title><gtr:parentPublicationTitle>Disease models &amp; mechanisms</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/edeb76ec9584c9365930d349525b1cca"><gtr:id>edeb76ec9584c9365930d349525b1cca</gtr:id><gtr:otherNames>Jones DT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1754-8403</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/985D040F-4B9F-471B-A09B-B1F3261E909E"><gtr:id>985D040F-4B9F-471B-A09B-B1F3261E909E</gtr:id><gtr:title>The role of ?3-integrins in tumor angiogenesis: context is everything.</gtr:title><gtr:parentPublicationTitle>Current opinion in cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3b6fd53de1aa7f489ba2f8448bb3deca"><gtr:id>3b6fd53de1aa7f489ba2f8448bb3deca</gtr:id><gtr:otherNames>Robinson SD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0955-0674</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/993C9D99-5A6A-4A45-9197-80C848591D4D"><gtr:id>993C9D99-5A6A-4A45-9197-80C848591D4D</gtr:id><gtr:title>Exploring Novel Methods for Modulating Tumor Blood Vessels in Cancer Treatment.</gtr:title><gtr:parentPublicationTitle>Current biology : CB</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5de8c9693ebabc4a54896aac7d61681d"><gtr:id>5de8c9693ebabc4a54896aac7d61681d</gtr:id><gtr:otherNames>Wong PP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0960-9822</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9D0B46E1-DD66-4DC4-AC90-6FC159E06C0B"><gtr:id>9D0B46E1-DD66-4DC4-AC90-6FC159E06C0B</gtr:id><gtr:title>Measuring angiogenesis in mice.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/678080c2bc9979d4354d26836d0a6212"><gtr:id>678080c2bc9979d4354d26836d0a6212</gtr:id><gtr:otherNames>Tavora B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/81D95408-3A10-44B6-BF4D-5C4075D76510"><gtr:id>81D95408-3A10-44B6-BF4D-5C4075D76510</gtr:id><gtr:title>Gene expression analysis in human breast cancer associated blood vessels.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/edeb76ec9584c9365930d349525b1cca"><gtr:id>edeb76ec9584c9365930d349525b1cca</gtr:id><gtr:otherNames>Jones DT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4160BB15-0E72-4EFB-805A-1BBBB5CF86F5"><gtr:id>4160BB15-0E72-4EFB-805A-1BBBB5CF86F5</gtr:id><gtr:title>Fascin 1 is dispensable for developmental and tumour angiogenesis.</gtr:title><gtr:parentPublicationTitle>Biology open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/417d43a7089aa342f399b24e0f14fc1c"><gtr:id>417d43a7089aa342f399b24e0f14fc1c</gtr:id><gtr:otherNames>Ma Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2046-6390</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F66A2D0D-FA3F-4B32-AB90-49AAD67B3F3F"><gtr:id>F66A2D0D-FA3F-4B32-AB90-49AAD67B3F3F</gtr:id><gtr:title>Dual-action combination therapy enhances angiogenesis while reducing tumor growth and spread.</gtr:title><gtr:parentPublicationTitle>Cancer cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5de8c9693ebabc4a54896aac7d61681d"><gtr:id>5de8c9693ebabc4a54896aac7d61681d</gtr:id><gtr:otherNames>Wong PP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1535-6108</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B9400BEC-3D42-4635-99CF-BD8BF110D69C"><gtr:id>B9400BEC-3D42-4635-99CF-BD8BF110D69C</gtr:id><gtr:title>FAK-heterozygous mice display enhanced tumour angiogenesis.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/47a51de9308dc38175917e4f755927ab"><gtr:id>47a51de9308dc38175917e4f755927ab</gtr:id><gtr:otherNames>Kostourou V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/609441DF-EFFF-4246-8A04-0250D3B883F1"><gtr:id>609441DF-EFFF-4246-8A04-0250D3B883F1</gtr:id><gtr:title>FAK-heterozygous mice display enhanced tumour angiogenesis.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ef4149ccc533c98d0def3e3513beaafe"><gtr:id>ef4149ccc533c98d0def3e3513beaafe</gtr:id><gtr:otherNames>Kostourou V.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/531439FC-3839-4DF7-A6EA-75BC07B0BD24"><gtr:id>531439FC-3839-4DF7-A6EA-75BC07B0BD24</gtr:id><gtr:title>The endothelial transcription factor ERG promotes vascular stability and growth through Wnt/?-catenin signaling.</gtr:title><gtr:parentPublicationTitle>Developmental cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/154f350c09993bf73b921298856f1984"><gtr:id>154f350c09993bf73b921298856f1984</gtr:id><gtr:otherNames>Birdsey GM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1534-5807</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1B3F5C4E-50F1-45CE-8985-D7BB9408292C"><gtr:id>1B3F5C4E-50F1-45CE-8985-D7BB9408292C</gtr:id><gtr:title>Focal adhesion kinase and tumour angiogenesis.</gtr:title><gtr:parentPublicationTitle>The Journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/dcf345c3ea2f5e32de40ba1c80b0a48c"><gtr:id>dcf345c3ea2f5e32de40ba1c80b0a48c</gtr:id><gtr:otherNames>Lechertier T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-3417</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8CF589AC-5393-4F85-90C5-79E3CC81C8CD"><gtr:id>8CF589AC-5393-4F85-90C5-79E3CC81C8CD</gtr:id><gtr:title>Use of the mouse aortic ring assay to study angiogenesis.</gtr:title><gtr:parentPublicationTitle>Nature protocols</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/549cbf805ce7d8520d8a40810c6b0188"><gtr:id>549cbf805ce7d8520d8a40810c6b0188</gtr:id><gtr:otherNames>Baker M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1750-2799</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0901609</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>